Ceftazidime, a new broad-spectrum cephalosporin, was administered to 30 patients with serious bacterial infections in a randomized dosing trial with daily doses of 1.5 or 3 g. Both regimens were equally efficacious, with satisfactory clinical responses in 28 instances (93%) and microbiological eradication of 79%o of initial bacterial isolates. The development of resistance to ceftazidime during therapy was observed in three cases (Enterobacter agglomerans, Enterobacter cloacae, and Pseudomonas aeruginosa) and superinfection by a resistant Enterobacter agglomerans strain occurred in one case. Adverse reactions of clinical significance included one case each of leukopenia, azotemia, diarrhea (Clostridium dijficile toxin positive), and rash.
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With new 3-lactam antibiotics, we now are able to treat infections due to cephalothin-resistant bacteria that ordinarily require aminoglycoside therapy. Because many of these infections occur in patients who may have some degree of renal impairment, the additional nephrotoxicity of aminoglycosides may be undesirable in this setting. The new 1-lactams, including ceftazidime (GR 20263), appear to be free of this side effect (3) . Moreover, ceftazidime has markedly increased activity in vitro against most gramnegative bacilli, especially Pseudomonas aeruginosa and Serratia marcescens (4, 5) . Therefore, we evaluated the efficacy and safety of ceftazidime in a randomized dosing trial.
MATERIALS AND METHODS
Patient seectio. Patients were admitted to the study if they had clinical symptoms and signs of infection of bone, soft tissue, or respiratory tract, which were confirmed by isolation of a ceftazidime-susceptible culture immediately preceding the initiation of therapy. If cultures obtained at the initiation of therapy were sterile or yielded ceftazidime-resistant organisms, the patient was dropped from the study while safety testing was continued. Susceptibility to ceftazidime was determined for each isolate by the Group B similarly included seven patients with underlying diseases: one comatose patient with a tracheostomy and pneumonia, gastric carcinoma in a patient with a postoperative polymicrobial hepatic abscess, peripheral vascular disease in a patient with an infected plantar ulcer, rheumatoid arthritis and chronic renal failure in a case of osteomyelitis, acute renal failure in a case of septicemia from mediastinitis, and an obstructed common bile duct (with an external drainage tube) in a case of polymicrobial cholangitis.
The infections varied in severity, however, between the two groups. Group A consisted of three patients with osteomyelitis, two with respiratory tract infections, and 11 with skin and soft tissue infections. Group B consisted of two patients with osteomyelitis and one with septic arthritis, two with respiratory tract infections (including one with septicemia) and one with empyema, four with skin and soft tissue infections (including one with septicemia), and four with intraabdominal infections, including a subhepatic abscess, an intrahepatic abscess, a diverticular abscess, and cholangitis. Thus, group B contained more severe infections-the intraabdominal infections and septicemias.
Bacteria cultured initially were comparable in both groups. Group A consisted of 23 isolates, including Pseudomonas aeruginosa (9), Serratia marcescens (4), Enterobacter cloacae (1) (3), and a single isolate of Aeromonas hydrophila. No anaerobic bacteria were isolated from these wounds, and this fact reflects our intentional selection bias towards aerobic and facultative gram-negative bacilli in this study. These bacteria were all shown to be ceftazidime-susceptible by disk testing. MICs were determined for most isolates ( Table 1 ). The MICs (in micrograms per milliliter) were as follows: Pseudomonas aeruginosa, 0.6 to 6.2 (mean, 3.0); Enterobacter species, 1.2 to 2.5 (mean, 1.6); Serratia marcescens, 1.5; Proteus species, 0.6 to 1.5 (mean, 1.0); K. pneumoniae, 0.5 to 1.5 (mean, 0.9); Escherichia coli, 0.8 to 1.5 (mean, 0.9); Aeromonas hydrophila, 0.8; and M. morganii, 1.3. A total of seven infections were polymicrobial (five in group A and two in group B).
Efficacy. There was a satisfactory clinical response in 15 of 16 infections in group A (94%) and 13 of 14 infections in group B (93%). Of these infections, 10 were cured and 5 improved in group A, whereas 9 were cured and 4 improved in group B. In group A, cures were achieved in five Pseudomonas infections, one Morganella infection, one Serratia infection, one Staphylococcus aureus infection, and three polymicrobial infections. The patients regarded as improved instead of cured in group A required either discontinuation of the antibiotic owing to an adverse drug reaction (leukopenia in patient S-25) or, for outpatient therapy (Bactrim in case S-3 and tobramycin in patient R-4), further surgical debridement (patient S-16), or they expired from other causes (renal failure in patient S-2). In group B, cures were effected in four Pseudomonas infections, one Staphylococcus aureus infection, one Klebsiella infection, one Proteus mirabilis infection, one Enterobacter cloacae infection, and one polymicrobial infection. The patients who were regarded as improved instead of cured required further local care after discontinuing the drug (patients S-5, S-8, S-9, and S-23).
There were two clinical failures on ceftazi- leukopenia (two patients), abnormal creatinine (two patients), diarrhea (two patients), and rash (one patient). The eosinophilia ranged from 418 to 624/mm3 (mean, 487) and occurred a mean of 15 days into therapy. It was not associated with rash or leukopenia. The liver function abnormalities involved clinically insignificant elevations of aspartate transaminase to a mean height of 137 IU/ml, occurring a mean of 12 days into therapy. They occurred in patients in whom the alkaline phosphatase levels were elevated at the start of therapy and therefore may not have been drug related.
In four instances, the abnormalities were considered severe enough to warrant discontinuation of the drug. One patient (R-6, group B) developed a rash after 8 days of therapy, and the drug was stopped. Two patients had diarrhea and were tested for C. difficile toxin in the stool; the drug was terminated in the one with the positive assay. The patient (S-13, group A) responded to oral vancomycin. Ceftazidime treatment resulted in two cases of leukopenia. In one patient (S-12, group A), the leukocyte count reached a nadir of 4,300/mm3, with 22% polymorphonuclear leukocytes by day 11 of therapy. In the second patient (S-25, group A), the nadir of 3,100/mm3 with 73% polymorphonuclear leukocytes occurred by day 16 In our study, the two groups were not only heterogeneous as to the types of infections but also not strictly comparable, since both septicemias and all four intraabdominal infections were in one group. Because the patients in this group were initially more seriously ill with life-threatening infections, no definite conclusions can be derived regarding dosing, except that moderately ill patients can be treated with a lower dosage (1.5 g daily), whereas more critically ill patients might benefit from a higher dosage (3 g daily). However, since the serum levels (peak and trough) in the lower dosage group are so much higher than the MICs of these cephalothin-resistant organisms, it may not matter which dosage regimen is used as long as serum levels and MICs are monitored.
The one cephalothin-resistant facultative gram-negative bacillus that may well be a problem for ceftazidime is Enterobacter. One of the two clinical failures occurred in a patient superinfected with a susceptible Enterobacter agglomerans strain that became resistant to ceftazidime during therapy. Another patient was superinfected with a de novo resistant Enterobacter agglomerans strain. Development of resistance during therapy was also noted in Enterobacter cloacae and Pseudomonas aeruginosa. Mucocutaneous candidiasis was a minor inconvenience in four instances, and only three cases of Streptococcus faecalis colonization were noted during therapy. These phenomena occurred in both dosage regimens. The phenomenon of wound colonization with resistant organisms is of potential importance to the development of a reservoir of resistant pathogens causing nosocomial infections.
The MICs of Staphylococcus aureus and Bacteroides fragilis are fairly high with respect to ceftazidime. We therefore purposefully did not treat anaerobic infections with ceftazidime and limited the number of Staphylococcus aureus infections. Nonetheless, in the three Staphylococcus aureus infections that we treated, in which the organisms were found to be susceptible, clinical cure and microbiological eradication were obtained. Both dosage regimens were effective, although we feel more comfortable with higher doses with this pathogen.
Ceftazidime was generally well tolerated except in four instances, leukopenia, C. difficile toxin-induced diarrhea, rash, and mild azotemia, which required discontinuation of the drug. The side effects were not dose related except possibly in the case of azotemia. Though there are other explanations as to the etiology of the azotemia, we would sound a precautionary note for monitoring renal function carefully in seriously ill patients treated with ceftazidime, based on the structural similarity at the 3-position of the dihydrothiazolidine ring between ceftazidime and cephaloridine, a cephalosporin with known nephrotoxic potential. Even though it was obviously quite effective in treating serious cephalothin-resistant gram-negative bacillary infections, we must also advise following patients especially closely for the development of resistance in Enterobacter and Pseudomonas species during treatment.
